Project Grant R21TW012879
- This federal Project Grant award of $709,872 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop and pilot test a couple-based intervention to address perinatal depression and improve adherence to prevention of mother-to-child transmission (PMTCT) of HIV in Malawi. The key objectives are to: 1) develop a couple-based intervention using problem-solving therapy and content on couple...
- Federal Grant Award Summary The National Institute of Child Health and Human Development (NICHD) awarded a Project Grant totaling $996,169 to Harvard T.H. Chan School of Public Health, with an award date of September 15, 2025, and completion deadline of June 30, 2030. Under the Child Health and Human Development Extramural Research program (CFDA 93.865), this award funds the TSEPAMO Next Generation research initiative, which will produce two primary deliverables: (1) clinical evidence...
- Grant Award Summary The National Institute of Child Health and Human Development (NICHD) awarded the University of Washington a $466,500 project grant (CFDA 93.865 – Child Health and Human Development Extramural Research) effective September 25, 2025, through August 31, 2027. This research project evaluates isoniazid (INH) exposure during pregnancy among women living with HIV (WLHIV) and their infants, with a focus on measuring cumulative maternal and fetal drug exposure and assessing associated...
- This federal Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) totaling $945,397 provides funding to the Magee-Womens Research Institute and Foundation, with a sub-award to the University of Pittsburgh, to adapt and evaluate a collaborative care model (CCM) for treating pregnant persons with opioid use disorder (OUD) in low-resource obstetric settings. The key objectives are to: 1) adapt the CCM for rural and low-resource...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $381,487 to the University of Maryland, Baltimore (UMB) to assess the early implementation of long-acting injectable cabotegravir (CAB-LA) pre-exposure prophylaxis (PrEP) among adolescent girls and young women (AGYW) at high risk of HIV acquisition in Zambia. The key objectives are to: 1) Evaluate implementation determinants of CAB-LA...
- This Project Grant award in the amount of $431,712, funded by the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to improve HIV testing among children under five in rural Uganda. The primary goal is to engage with traditional healers to facilitate HIV counseling and testing via oral swab antigen tests for this vulnerable pediatric population. The award supports two key activities: 1) determining barriers and...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Massachusetts General Hospital $691,293 under the Allergy and Infectious Diseases Research program (CFDA 93.855) for a one-year project grant effective January 1, 2026 through December 31, 2026. The research project, titled "Impact of In Utero HIV and Antiretroviral Exposure on the Placenta and Birth Weight," will investigate the effects of antiretroviral therapy (ART) and HIV...
- This federal Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), provides $494,251 to the University of California, Los Angeles (UCLA) to conduct a community-partnered, multi-site randomized trial on the impact of a medical-financial partnership intervention on parent mental health, perinatal outcomes, and child developmental risk. The intervention aims to...
- Federal Cooperative Agreement Summary Award: Optimal Dosing of Understudied Drugs Administered to Pregnant Individuals Per Standard of Care (PregDose) Funding Agency: National Institute of Child Health and Human Development (NICHD) CFDA Program: Child Health and Human Development Extramural Research (93.865) Awardee: George Washington University Award Amount: $1,869,596 Award Date: August 1, 2025 | Completion Date: May 31, 2030 George Washington University will establish research...
- Federal Grant Award Summary The National Institute of Child Health and Human Development (NICHD) awarded a $323,470 Project Grant to Metis Foundation on July 1, 2025, under the Child Health and Human Development Extramural Research program (CFDA 93.865). This five-year award, concluding June 30, 2030, supports the development and pilot testing of a single-session cognitive-behavioral therapy (CBT)-informed virtual intervention targeting loss-of-control (LOC) eating during pregnancy. The research...
GROW: ADAPTING AND ENHANCING GROUP-BASED PRENATAL CARE TO SUPPORT HEALTHY GESTATIONAL WEIGHT GAIN FOR HIV-AFFECTED WOMEN - ABSTRACT: SUBOPTIMAL GESTATIONAL WEIGHT GAIN (GWG) IS A MODIFIABLE RISK FACTOR FOR ADVERSE PREGNANCY OUTCOMES, POSTPARTUM WEIGHT RETENTION AND OBESITY, AND SUBSEQUENTLY, THE LONG-TERM DEVELOPMENT OF NON-COMMUNICABLE DISEASES (NCD) AMONG WOMEN AND CHILDREN. IN SOUTH AFRICA, 45% OF WOMEN EXCEED THE INSTITUTE OF MEDICINE'S (IOM) RECOMMENDED WEIGHT GAIN IN PREGNANCY, AND 38% GAIN TOO LITTLE WEIGHT, PUTTING THEM AT RISK FOR POOR PERINATAL AND POSTPARTUM NCD OUTCOMES. WOMEN IN LOW- AND MIDDLE-INCOME COUNTRIES (LMICS) WITH A HIGH BURDEN OF HIV AND NCDS, SUCH AS SOUTH AFRICA, ARE AT PARTICULARLY HIGH RISK OF SUBOPTIMAL WEIGHT GAIN DUE TO POOR DIET QUALITY, LIMITED PHYSICAL ACTIVITY, HIGH LEVELS OF PSYCHOSOCIAL STRESSORS, AND, FOR WOMEN WITH HIV (WHIV), POSSIBLE ANTIRETROVIRAL-ASSOCIATED WEIGHT GAIN. BY SUPPORTING HEALTHY GWG, THERE IS STRONG POTENTIAL TO REDUCE POSTPARTUM NCD RISK AND IMPROVE PERINATAL OUTCOMES FOR WOMEN WITH AND WITHOUT HIV. HOWEVER, FEW GWG INTERVENTIONS ARE AVAILABLE FOR DELIVERY IN LMICS, AND NONE HAVE BEEN ADAPTED TO ADDRESS EXCESSIVE AND INADEQUATE GWG OR ENHANCED TO MEET THE UNIQUE NEEDS OF WOMEN WITH AND WITHOUT HIV. TO ADDRESS THIS GAP, OUR TEAM PREVIOUSLY DEVELOPED AN INNOVATIVE, THEORETICALLY DRIVEN GROUP PRENATAL CARE (GPNC) INTERVENTION AND ADAPTED IT TO REDUCE GWG AND NCD (GPNC-NCD) RISK IN RESOURCE-CONSTRAINED SETTINGS. GPNC-NCD IS AN EVIDENCE-BASED INTERVENTION, BASED ON SOCIAL COGNITIVE THEORY, THAT BUILDS HEALTH LITERACY, SELF-EFFICACY, SOCIAL SUPPORT, AND SATISFACTION WITH CARE, LEADING TO IMPROVED PERINATAL, GWG, NCD, AND PERINATAL OUTCOMES. THE GOAL OF THIS PROPOSAL IS TO ADAPT THE GPNC-NCD INTERVENTION FOR USE IN SOUTH AFRICA TO SUPPORT HEALTHY GWG (NOT TOO MUCH OR TOO LITTLE), ENHANCE IT TO ADDRESS THE NEEDS OF WHIV AND WITHOUT HIV, AND EVALUATE THE FEASIBILITY, ACCEPTABILITY, AND PRELIMINARY EFFICACY OF THE INTERVENTION TO IMPROVE GWG, NCD, PERINATAL, AND HIV CARE AND PREVENTION OUTCOMES IN A PILOT RANDOMIZED TRIAL. OUR SPECIFIC AIMS ARE: 1) TO ADAPT THE GPNC-NCD INTERVENTION FOR USE IN SOUTH AFRICA TO SUPPORT HEALTHY GWG AND ENHANCE IT TO ADDRESS HIV STATUS AS A DRIVER OF GWG, AND 2) TO DETERMINE THE FEASIBILITY, ACCEPTABILITY, AND PRELIMINARY EFFICACY OF THE ADAPTED AND ENHANCED GPNC INTERVENTION. IN A PILOT TRIAL, 80 WOMEN WILL BE INDIVIDUALLY RANDOMIZED BY HIV STATUS AT 14 WEEKS GESTATION TO GPNC (N=20 WHIV, N=20 HIV-) VERSUS USUAL CARE (N=20 WHIV, N=20 HIV-). WE HYPOTHESIZE THAT ADAPTED GPNC WILL BE FEASIBLE, ACCEPTABLE AND SHOW PRELIMINARY EFFICACY TO IMPROVE GWG, NCD (BLOOD PRESSURE, BREASTFEEDING, DIET, PHYSICAL ACTIVITY), HIV CARE/PREVENTION (ART ADHERENCE, VIRAL SUPPRESSION, OR PREP UPTAKE), AND PERINATAL (BIRTHWEIGHT, LARGE-FOR-GESTATIONAL AGE, CESAREAN DELIVERY) OUTCOMES. THIS PROPOSAL ADDRESSES THE GOALS OF PAR-23-191 BY LEVERAGING THE EVIDENCE-BASED GPNC INTERVENTION TO SUPPORT HEALTHY GWG, ADDRESSES HIV-NCD DISPARITIES, AND BUILDS CAPACITY FOR HIV/NCD RESEARCH IN LMICS. IF SUCCESSFUL, OUR ADAPTED GPNC INTERVENTION HAS STRONG POTENTIAL TO SERVE AS A MODEL FOR HOW TO INTEGRATE NCD AND HIV CARE AND PREVENTION SUPPORT INTO ROUTINE PRENATAL CARE IN LMICS TO IMPROVE PERINATAL, HIV, AND NCD OUTCOMES.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $92.3k | 2/13/26 |